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Effect of African potato (Hypoxis hemerocallidea) on the 
pharmacokinetics of efavirenz
Seloi Mogatle, Michael Skinner, Edward Mills, Isadore Kanfer
The use of natural health products (NHPs) as traditional 
medicines (TMs) among people living with HIV/AIDS is 
widespread, although their effects on the pharmacokinetics 
of antiretroviral medicines (ARVs) have not been established. 
The African potato (AP) received strong support from the 
former Minister of Health for use as an immune booster for 
HIV-positive patients, and is purported to be one of the best-
selling NHPs in South Africa. Those taking TMs believe that 
they are effective and have few or no side-effects compared 
with current ARVs.1 The use of TMs is high among indigenous 
people in South Africa,2,3 with 33.5% of those living with 
HIV/AIDS4 using them to manage HIV symptoms. Patients 
receiving ARVs commonly take NHPs concurrently with their 
therapy despite there being little or no published information 
on the effectiveness and possibility of inter-interactions. In the 
Eastern Cape province of South Africa, the highest selling NHP 
was AP, at 11 tons/year.5 The corm of the AP is traditionally 
used for the treatment of urinary infections;6,7 among people 
living with AIDS, 64% of those who use TMs, use the AP.2 In 
vitro and in vivo data have suggested that the AP has immune-
boosting properties.8,9
Concomitant use of NHPs with orthodox medicines may 
affect the pharmacokinetics and pharmacodynamics through 
drug interaction mechanisms.10-12 NHPs can affect CYP450 
enzymes and result in an increase or decrease in plasma 
concentrations of substrates which are metabolised by these 
enzyme systems. Possible effects of co-administration of NHPs 
and ARVs include increased side-effects of ARVs and losing the 
control of viral replication, which could lead to non-compliance 
and therapeutic failure, respectively.13,14
Hypoxoside, the main component of the AP,15 is not absorbed 
through the gut but is extensively metabolised in the colon 
by β-glucosidase to rooperol, which is then absorbed into 
the bloodstream16,17 and undergoes further metabolism to 
glucuronides and sulphates. In vitro studies have shown that 
hypoxoside induces the transporter protein, p-glycoprotein 
(P-gp) in Caco-2 cells, and stigmasterol, which is a constituent 
of AP, and rooperol both exhibited high inhibition of CYP3A4, 
3A5 and CYP19 enzymes.18 Ingestion of the AP may therefore 
have the potential to affect both transporters and enzymes and 
consequently interfere with the absorption and metabolism of 
concurrently administered therapeutic agents.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) which is effective against HIV-1 infection and is the 
backbone of highly active antiretroviral therapy (HAART) 
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Purpose. The purpose of this study was to evaluate the 
effect of the African potato (AP) on the pharmacokinetics of 
efavirenz.
Methods. A single-dose, two-phase sequential study was 
conducted over 31 days in 10 healthy volunteers. On day 
1 of the study, volunteers were administered a 600 mg 
efavirenz tablet, and blood samples were collected before 
dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 
36 and 48 hours after dosing. From day 16, a traditionally 
prepared AP decoction was administered daily until day 30. 
On day 29, volunteers were administered a single 600 mg 
dose of efavirenz, as was done on day 1. Plasma samples 
were harvested immediately after blood sample collection 
and frozen at –80ºC until assayed. Plasma concentrations of 
efavirenz were determined by a validated high performance 
liquid chromatography (HPLC) method with UV detection, 
and pharmacokinetic parameters were calculated. Geometric 
mean ratios of Cmax and AUC0-48 of efavirenz before and after 
co-administration of 14 successive daily doses of AP were 
compared.
Results. All subjects completed the study. The geometric 
mean ratios of Cmax and AUC0-48 were 97.30 and 102.82 with 
corresponding 90% confidence intervals (CIs) of 78.81 - 120.14 
and 89.04 - 118.80, respectively.
Conclusion. Pharmacokinetic data generated during this 
study indicated that AP did not significantly alter the 
pharmacokinetics of efavirenz. Hence, co-administration of 
AP is unlikely to affect the clinical usage of efavirenz.
S Afr Med J 2008; 98: 945-949.
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in South Africa.19 Efavirenz is a substrate of both CYP3A4 
and CYP2B6,20 and the metabolites are 7-hydroxyefavirenz, 
8-hydroxyefavirenz and 8,14-dihydroxyefavirenz. It has a 
long half-life (of 52 - 76 hours) when administered as a single 
dose and 40 - 55 hours after multiple doses. The reduced half-
life after multiple doses is due to metabolic auto-induction. 
Efavirenz is not a substrate of P-gp21 and therefore the 
absorption of efavirenz is unlikely to be affected by inducers or 
inhibitors of P-gp.
Since efavirenz and AP have been shown to be CYP450 
enzyme substrates, the possibility exists of interaction between 
them when simultaneously administered. Reports have 
indicated that AP inhibits CYP3A4 in vitro.18 However, to our 
knowledge there is no published information that this occurs 
in vivo. We therefore investigated whether the concurrent 
administration of AP would affect the pharmacokinetics 
and subsequent clinical performance of efavirenz in human 
subjects.
Materials and methods
The HPLC system consisted of a Waters model 515 HPLC 
pump, a model 715 autosampler and a model 2995 PDA UV 
detector (Waters, Milford, MA, USA). Efavirenz was donated 
by Aspen Pharmacare (Port Elizabeth) and diclofenac sodium 
(DIC) was purchased from Sigma-Aldrich (Johannesburg). 
Acetonitrile and methanol of HPLC grade were purchased 
from Romil Ltd, Cambridge, UK, and formic acid 99.9% from 
Associated Chemical Enterprises, Johannesburg. Water was 
purified by reverse osmosis and filtration through a Milli-Q 
purification system (Millipore, Milford, MA, USA). Human 
plasma with potassium edentate (K-EDTA) as an anticoagulant 
was obtained from South African National Blood Services, Port 
Elizabeth.
Study population
Ten healthy, non-smoking, HIV-negative male subjects were 
enrolled after giving informed consent. Eligibility criteria 
included age between 18 and 55 years and a body mass index 
(BMI) between 19 and 30 kg/m2. Pre-study medical screening 
was performed within a month of initiating the study, and 
volunteers who passed the physical, medical and laboratory 
screening tests were enrolled. Laboratory tests included tests 
for liver function, hepatitis B and C, HIV, blood biochemistry, 
urinalysis and drugs of abuse (including amphetamines, 
barbiturates, benzodiazepines, cocaine, methamphetamine, 
morphine, phencyclidine, THC and TCA).
Prescription and over-the-counter medicines were restricted 
from 1 week before each phase until the last blood sample had 
been taken at the end of the study. Consumption of alcohol 
was forbidden from 4 days before the study, and caffeine and 
grapefruit juice were restricted from 48 hours before the study. 
Volunteers were prohibited from strenuous exercise from 24 
hours before the study. 
Study design
Ethical approval was granted by the Rhodes University Ethical 
Standards Committee; the study was conducted according 
to the South African Good Clinical Trials guidelines22 and 
Declaration of Helsinki and its amendments.
A single-dose, two-phase sequential study was conducted 
in healthy male volunteers under fasting conditions. Phase 1 
started on day 1 and phase 2 started on day 29, each phase 
lasting 3 days. The washout period between the administration 
of the efavirenz doses was 28 days. The night before the study 
(day 0) volunteers were checked into the clinic and tested for 
drugs of abuse and alcohol consumption and questioned to 
ensure that they had complied with the study restrictions. 
Volunteers fasted for 10 hours before they were administered a 
600 mg efavirenz tablet with a 240 ml glass of water. Standard 
meals were provided until 24 hours after dosing, and the times 
at which meals were started and finished were recorded as well 
as the amounts consumed. Blood samples were collected in 
Vacutainers containing potassium EDTA as the anticoagulant at 
the following time intervals: before dosing (0) and at 0.5, 1, 1.5, 
2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after dosing.
From day 16 until day 30 of the study, volunteers were 
administered a freshly prepared traditional AP decoction, at a 
dose of 15 mg/kg/day of hypoxoside, at the same time daily 
for 14 consecutive days. The AP decoction was prepared and 
assayed for hypoxoside content prior to administration. After 
receiving 12 consecutive daily doses of the AP decoction, phase 
2 was initiated on day 28, when each of the volunteers received 
a 600 mg dose of efavirenz as at the beginning of the study. 
Blood samples were collected at the same time intervals as in 
phase 1.
Blood samples were centrifuged at 2 800 rpm for 10 minutes 
at 4°C, and plasma was harvested into two 2 ml polypropylene 
tubes (original and duplicate) and stored at –80ºC until 
assayed.
Safety and tolerability
Baseline laboratory and medical data were documented before 
the study. During the study, volunteers were monitored for any 
adverse events, which were documented. Blood pressure, pulse 
and body temperature were taken before and 4 hours after 
dosing with efavirenz. During the study, volunteers were asked 
open questions about their wellbeing. Post-study laboratory 
and medical tests were conducted within 4 days of the end of 
phase 2 and the results compared with the baseline data.
Preparation and analysis of AP
The AP decoction was prepared in the traditional manner as 
follows: After removing the roots, the corms (~250 g) were 
washed with clean water, grated and weighed, boiled in 2.5 
litres of water for 45 minutes, allowed to cool, and then mixed 
and strained with a clean muslin cloth before analysis. Two  
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10 ml samples of the AP preparation were placed in 20 ml 
Kimax centrifuge tubes and centrifuged in an IEC HN-
SII centrifuge (Damon/IEC Division, Needham HTS, 
Massachusetts, USA) at 3 000 rpm for 10 minutes. The 
supernatant was filtered using a 0.44 µm filter and the internal 
standard, sulphamerazine, was added to the mixture, which 
was diluted by a factor of 500 and re-filtered. The samples were 
analysed according to a method reported by Nair.23
Analysis of plasma samples
Plasma samples were analysed by a validated HPLC method, 
and separation was achieved on a Phenomenex Luna a C18(2) 
(5 µm, 150 x 5 mm i.d.) column maintained at a temperature of 
40±2ºC. The mobile phase consisted of acetonitrile: 0.1M formic 
acid (pH 2.30): methanol (52:43:5 v/v/v) at a flow rate of 0.3 
ml/min. The injection volume was 10 µl and the observed run 
time was less than 9 min. The eluent was monitored at  
λ = 247 nm and 275 nm for efavirenz and the internal standard, 
diclofenac sodium (DIC) respectively, using a photodiode array 
(PDA) detector.
An aliquot of 100 µl of plasma was precipitated with 200 µl 
DIC in mobile phase, the mixture was vortexed for 50 seconds 
and then centrifuged for 10 minutes at 13 500 rpm (10 000 g). 
About 100 µl of the supernatant was transferred to a micro-
insert and injected into the HPLC system.
Pharmacokinetic analysis
The pharmacokinetic parameters of efavirenz before and after 
co-administration with AP were determined using a non-
compartmental model.24 Exposure measures such as area under 
the curve (AUC) of the plasma concentration-time profiles 
from 0 hours to 48 hours (AUC0-48), and peak plasma EVF 
concentrations (Cmax) were used to assess the effect of AP on 
the pharmacokinetics of efavirenz. Other parameters that were 
monitored included the elimination half-life (t1/2), time taken 
to reach peak plasma concentration (tmax) and the elimination 
rate constant (k). The AUC0-48 and Cmax were calculated and the 
trapezoidal rule was used to estimate AUC0-48.
Statistical analysis
ANOVA analysis was conducted on Cmax and AUC0-48 using 
log-transformed data and the geometric mean ratios were 
calculated. The two one-sided t-test was used to determine the 
respective 90% CIs. An interaction would be concluded if the 
90% CIs for Cmax and/or AUC0-48 were found to be outside the 
limits of 80 - 125%.25
Results
Demographic characteristics
Of the 10 enrolled healthy male volunteers, 9 (90%) were black 
and 1 (10%) was white; their mean age was 23 (range 19 - 27 
years) and their BMIs ranged from 19.42 to 27.90 kg/m.2 All 
volunteers completed the study.
Pharmacokinetics of efavirenz
The mean plasma concentration/time profiles of efavirenz 
alone (phase 1) and efavirenz co-administered with AP 
(phase 2) are shown in Fig. 1. Visual inspection of the profiles 
suggests that plasma concentrations of efavirenz were not 
significantly affected by co-administration of AP. The geometric 
mean ratios of Cmax and AUC0-48 were 97.30 and 102.82, and 
the corresponding 90% CIs were 78.81 - 120.14 and 89.04 
- 118.80, respectively. Whereas the 90% CI of the Cmax fell 
slightly outside the lower limit (78.81), the corresponding 
AUC0-48 values were within the limits of 80 - 125%. Hence, co-
administration of AP with efavirenz did not appear to affect 
the pharmacokinetics of efavirenz. Table I summarises the 
pharmacokinetic parameters.
Safety and tolerability
Laboratory tests for all volunteers were normal; no serious 
adverse effects were reported or noted during the study. 
However, 2 subjects reported dizziness, euphoria and 
sleepiness during phase 2; they had peak plasma efavirenz 
concentrations of 3.26 and 3.34 µg/ml, respectively, while the 
other volunteers had peak plasma concentrations <3.05 µg/ml.
Discussion
Although the 90% CIs for Cmax did not fall within the 80 - 125% 
interval, the acceptance limits for this parameter are generally 
considered to be less important than the AUC. Hence, the 
findings from this study suggest that interactions as a result of 
the co-administration of AP and efavirenz are unlikely. There 
was no significant change in the measured pharmacokinetic 
parameters of efavirenz when administered alone or 
concomitantly with AP.
In vitro hypoxoside inhibits CYP3A4 enzymes and also 
induces P-gp.18 This differs in vivo since hypoxoside is rapidly 
metabolised to rooperol following oral administration in 
Fig. 1. Mean plasma concentration of efavirenz alone and efavirenz co-administered with AP.
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Fig. 1. Mean plasma concentration of efavirenz alone and efavirenz co-
administered with AP.
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humans16 and is not absorbed per se. Therefore, only rooperol, 
the hypoxoside metabolite, enters the systemic circulation, 
where it is metabolised to form highly water-soluble 
glucuronides and sulphates. Hence, any effect on the CYP3A4 
enzymes following AP administration is unlikely to be due 
to hypoxoside. On the other hand, owing to the effective 
metabolism of rooperol, it is possible that concentrations of 
rooperol in the blood after oral consumption of AP are too 
low to significantly affect the activity of the CYP3A4 enzyme 
system.
It is suggested that efavirenz is mainly metabolised by 
CYP2B6 and to a lesser extent CYP3A4.20 Whereas hypoxoside 
and rooperol have been shown to affect CYP3A4 in vitro, 
and since the pharmacokinetics of efavirenz were not altered 
following co-administration of AP, components of AP probably 
do not affect CYP2B6 enzymes. Some other constituents of 
AP such as stigmasterol, however, were also found to inhibit 
CYP3A4 in vitro but the activity of stigmasterol in vivo did not 
alter the pharmacokinetics of efavirenz in this study.
Even though hypoxoside is not absorbed into the blood, 
it could still induce P-gp in the stomach and small intestine 
because it is only metabolised in the colon; therefore, 
absorption of therapeutic agents which are substrates of P-gp 
could be affected. Notwithstanding, such an interaction is not 
expected to influence the plasma concentration of efavirenz 
since efavirenz is not a substrate of P-gp.21
Conclusions
The co-administration of AP with efavirenz in our study does 
not appear to affect the pharmacokinetics of efavirenz; hence, 
interference with efavirenz therapy is not expected. There is, 
however, a need to investigate the effect of AP on other ARVs, 
particularly those ARVs which are P-gp substrates or whose 
major metabolic pathway is via CYP3A4 isozymes.
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